Evolution of the Average Target: Amgen Inc.

Evolution of the Target Price: Amgen Inc.

Changes in Analyst Recommendations: Amgen Inc.

c2636e4aab724eeea4c3eb71.d0sFLazHl2yZOri48tTvAXbd24GHbIV0fJ8-oePeWso.JiA0WNqo-Q_cbf_1k6WkMzqN6tW0Itw_KMlTxduXY409P0dc6ILyJt5yyw~6b3bb2f7d3a78aaa7df9e84f8aeaf002
Sep. 28 Scotiabank Raises Amgen Price Target to $500 From $450, Sector Outperform Rating Kept MT
Sep. 23 Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating MT
Sep. 10 HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445 MT
Sep. 08 Amgen's Olpasiran May Still Show Heart-Risk Reduction Despite Novartis Miss, UBS Says MT
Sep. 08 Rothschild & Co Redburn Adjusts Price Target on Amgen to $225 From $235, Keeps Sell Rating MT
Sep. 08 BMO Capital Downgrades Amgen to Market Perform From Outperform, Price Target is $450 MT
Sep. 08 Analyst recommendations: Amgen, Equifax, Lockheed Martin, Phillips 66, Valero Energy… Zonebourse
Sep. 07 Analyst recommendations: Amgen, Broadcom, Lululemon, Palo Alto Networks… Zonebourse
Sep. 04 Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating MT
Aug. 20 Piper Sandler Adjusts Price Target on Amgen to $457 From $427, Maintains Overweight Rating MT
Aug. 19 Argus Research Adjusts Amgen Price Target to $460 From $375, Maintains Buy Rating MT
Aug. 19 Morgan Stanley Adjusts Price Target on Amgen to $362 From $351, Keeps Equalweight Rating MT
Aug. 18 Mizuho Adjusts Price Target on Amgen to $352 From $303, Maintains Neutral Rating MT
Aug. 18 Cantor Fitzgerald Adjusts Price Target on Amgen to $400 From $350, Maintains Neutral Rating MT
Aug. 17 Mizuho Securities Adjusts Amgen Price Target to $352 From $303 MT
Aug. 13 Daiwa Securities Adjusts Price Target on Amgen to $430 From $390, Keeps Outperform Rating MT
Aug. 13 Barclays Adjusts Price Target on Amgen to $380 From $360, Maintains Equalweight Rating MT
Aug. 10 HSBC Adjusts Price Target on Amgen to $445 From $425, Keeps Buy Rating MT
Aug. 07 Citigroup Adjusts Price Target on Amgen to $405 From $345, Maintains Neutral Rating MT
Aug. 06 Rothschild & Co Redburn Adjusts Amgen Price Target to $235 From $220, Maintains Sell Rating MT
Aug. 05 Bernstein Adjusts Price Target on Amgen to $345 From $335, Maintains Market Perform Rating MT
Aug. 05 UBS Adjusts Price Target on Amgen to $440 From $420, Maintains Buy Rating MT
Aug. 05 JPMorgan Adjusts Price Target on Amgen to $350 From $300, Maintains Neutral Rating MT
Aug. 05 Wells Fargo Adjusts Price Target on Amgen to $400 From $390, Maintains Equalweight Rating MT
Aug. 05 Leerink Partners Adjusts Price Target on Amgen to $395 From $355, Maintains Market Perform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-7.25%
+14.84%
+5.49%
+6.6%
+7.19%
+7.52%
+5.92%
+29.21%
+6.44%
+21.47%
Average +9.74%
Weighted average by Cap. +9.95%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
421.51USD
Average target price
390.94USD
Spread / Average Target
-7.25%
High Price Target
500.00USD
Spread / Highest target
+18.62%
Low Price Target
225.00USD
Spread / Lowest Target
-46.62%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. AMGN Stock
  4. Consensus Amgen Inc.